Search

Blue biotech emerges from the deep

Blue biotech is getting into its stride, as the tools of genomics and high throughput screening are applied to unlock the chemical diversity of the oceans.

Cytokine for treating autoimmune diseases ready for partnering

PharmaLinks, a business dedicated to commercialising pharmaceutical research, is looking for a development partner for an immunosuppressive cytokine with therapeutic potential in inflammatory diseases including rheumatoid arthritis, asthma, COPD and arteriosclerosis.

After the float: Imperial Innovations

How will Imperial College London's newly floated tech-transfer affiliate invest its stock-market millions? After raising the money, now comes the fun part: spending it.

Creative Commons: Benkler and Lessig practice what they preach

Yochai Benkler and Lawrence Lessig are two well-known law professors affiliated with very prestigious US universities, Yale and Stanford, respectively. They are specialised in intellectual property like policemen are specialised in crime: it is their bailiwick but they do not particularly like it.

Lawyers on the nano case

The American Bar Association makes available its take on the USA's "federal environmental statutes" and their implications for nanotechnology.

Dental Implant battlefield

The IP battlefield is large and diversified. It goes way beyond highly-publicized battles about patenting genes or semi-conductor designs. A case in point is a lawsuit filed July 14 by Materialise nv, a spin-off of Belgium’s Katholieke Universiteit Leuven, against a Swiss-Swedish company, Nobel Biocare.

EU seeks views on knowledge transfer

You have until the end of the month to tell the EU about your "needs in relation to transnational research cooperation and knowledge transfer between public research organisations".

Stem cell issue could derail FP7 at the 11th hour

The European Union’s €54 billion research budget for the next seven years may not be approved in time for the beginning of next year – if Slovenia carries out its threat to oppose the funding of stem cell research.

£181M price tag set for Imperial Innovations float

The technology-transfer unit of Imperial College London, continuing preparations for its stock-market debut on 31 July, said it has completed a £25 million private placement and set a public share price that would value the business at £181 million.